After having identified activated immune signaling pathways as a key feature of GSCs vulnerable to TAK1 inhibition we next investigated the predictive nature of these signatures on an independent panel of 45 patient-derived GSCs cultures (Glioma Cellular Genetics Resource, GCGR). The gene discussed is MAP3K7; the disease is glioma.